Breaking Finance News

Vetr Inc. upgraded Horizon Pharma PLC (NASDAQ:HZNP) to Strong-Buy in a report released today.

Vetr Inc. has upgraded Horizon Pharma PLC (NASDAQ:HZNP) to Strong-Buy in a report released on 10/03/2016.

Just yesterday Horizon Pharma PLC (NASDAQ:HZNP) traded 2.65% higher at $18.44. The company’s 50-day moving average is $19.72 and its 200-day moving average is $17.66. The last stock close price is up 5.39% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,431,369 shares of the stock were exchanged, down from an average trading volume of 3,785,680

See Chart Below

Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma PLC has a 52 week low of $12.86 and a 52 week high of $23.70 The company’s market cap is currently $0.

In addition to Vetr Inc. reporting its target price, a total of 13 brokers have issued a report on the stock. The consensus target price is $30.23 with 4 brokers rating the stock a strong buy, 6 brokers rating the stock a buy, 1 broker rating the stock a hold, 1 broker rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Horizon Pharma PLC (NASDAQ:HZNP)

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units. Its segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. Its marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It also developed DUEXIS and RAYOS, known as LODOTRA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *